mRNA-based therapeutics — developing a new class of drugsUğur Şahin, Özlem Türeci|Nature Reviews Drug Discovery|2014Cited by 2.4k
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responsesUğur Şahin, Özlem Türeci|Nature|2020Cited by 2k
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humansUğur Şahin, Özlem Türeci|Nature|2021Cited by 828
Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non‐small‐cell lung cancerPatrick Micke, Özlem Türeci|International Journal of Cancer|2014Cited by 132
Ki-ras oncogene and p53 tumour suppressor gene mutations in colorectal carcinomas from the European Saar-Luxembourg region are less frequent than predicted by the classic adenoma-carcinoma sequence modelM. Pauly, Mario Dicato, Isabelle Kayser et al.|European Journal of Cancer|1997Cited by 8